These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24126799)

  • 1. Developing regulatory strategy for microbicides.
    Nardi R; Arterburn L; Carlton L
    Curr Top Microbiol Immunol; 2014; 383():137-52. PubMed ID: 24126799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbicides for prevention of HIV infection: clinical efficacy trials.
    Abdool Karim SS; Baxter C
    Curr Top Microbiol Immunol; 2014; 383():97-115. PubMed ID: 23695725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbicides for multidrug-resistant and multitropic HIV-1.
    D'Cruz OJ; Uckun FM
    Curr Opin Investig Drugs; 2008 Feb; 9(2):152-69. PubMed ID: 18246518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.
    Adamson CS; Freed EO
    Mol Interv; 2009 Apr; 9(2):70-4. PubMed ID: 19401538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidate microbicides and their mechanisms of action.
    Herrera C; Shattock RJ
    Curr Top Microbiol Immunol; 2014; 383():1-25. PubMed ID: 23612992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrospun fibers for vaginal anti-HIV drug delivery.
    Blakney AK; Ball C; Krogstad EA; Woodrow KA
    Antiviral Res; 2013 Dec; 100 Suppl():S9-16. PubMed ID: 24188701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of HIV prevention: prospects for an effective anti-HIV microbicide.
    Nuttall J; Romano J; Douville K; Galbreath C; Nel A; Heyward W; Mitchnick M; Walker S; Rosenberg Z
    Infect Dis Clin North Am; 2007 Mar; 21(1):219-39, x. PubMed ID: 17502237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and Perspectives on HIV-1 microbicide development.
    Alexandre KB; Mufhandu HT; London GM; Chakauya E; Khati M
    Virology; 2016 Oct; 497():69-80. PubMed ID: 27429040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbicides from a regulatory perspective.
    Stone AB; Harrison PF; Lusti-Narasimhan M
    AIDS; 2013 Sep; 27(14):2261-9. PubMed ID: 23612007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration.
    Dalmau D; Klimkait T; Telenti A
    Antivir Ther; 2005; 10(7):867-72. PubMed ID: 16312184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbicides-emerging essential pillars of comprehensive HIV/AIDS prevention.
    Gaym A
    Ethiop Med J; 2006 Oct; 44(4):405-15. PubMed ID: 17370443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
    Friend DR; Kiser PF
    Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbicides in the prevention of HIV infection: current status and future directions.
    Nuttall J
    Drugs; 2010 Jul; 70(10):1231-43. PubMed ID: 20568831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Running a tightrope: regulatory challenges in the development of antiretrovirals.
    Naeger LK; Struble KA; Murray JS; Birnkrant DB
    Antiviral Res; 2010 Jan; 85(1):232-40. PubMed ID: 19665489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical discovery and development of maraviroc for the treatment of HIV.
    Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
    Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Strategies to Defeat HIV.
    Serra-Moreno R; Gramberg T
    Curr HIV Res; 2016; 14(3):173-4. PubMed ID: 26957193
    [No Abstract]   [Full Text] [Related]  

  • 17. Microbicide dosage forms.
    Rohan LC; Devlin B; Yang H
    Curr Top Microbiol Immunol; 2014; 383():27-54. PubMed ID: 24220751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
    Martinez J; Coplan P; Wainberg MA
    Antiviral Res; 2006 Sep; 71(2-3):343-50. PubMed ID: 16787667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy.
    Murray JM
    J Infect Dis; 2003 Oct; 188(8):1258; author reply 1258-9. PubMed ID: 14551898
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicinal Plants Used in the Treatment of Human Immunodeficiency Virus.
    Salehi B; Kumar NVA; Şener B; Sharifi-Rad M; Kılıç M; Mahady GB; Vlaisavljevic S; Iriti M; Kobarfard F; Setzer WN; Ayatollahi SA; Ata A; Sharifi-Rad J
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.